I don't think I've ever laughed harder than during a church service, when something faintly ridiculous caught my eye. My friend saw it too, and once she started laughing, it became impossible to stop.

Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Nightmare night for Juventus, who experience a second half of rare ugliness in Istanbul and really compromise their ...

Nightmare night for Juventus, who experience a second half of rare ugliness in Istanbul and really compromise their ...

VolitionRx Limited ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover ...

Cellestia Biotech AG is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus. The ...